A prospective randomized controlled trial demonstrating significantly increased clinical pregnancy rates following 24 chromosome aneuploidy screening: biopsy and analysis on day 5 with fresh transfer

Scott, Richard T.; Tao, Xin; Taylor, Debbie; Ferry, K.M.; Treff, Nathan R.

doi:10.1016/j.fertnstert.2010.07.007

Cited by 44 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If embryos with a moderate/ low level of mosaicism will "correct" when developing to the blastocyst stage, then a higher proportion of embryos will be chromosomally normal. In a preliminary prospective RCT study by Scott et al 2010, the results of a 24-chromosome aneuploidy screening of a blastocyst stage embryo with fresh transfer demonstrated a significant improvement (12 of 13; 92%) as compared to controls (9 of 15; 60%) in clinical pregnancy rates [169].…”

Section: Diagnostic Challengesmentioning

confidence: 99%

Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?

Agarwal

Nagy

2011

J Assist Reprod Genet

View full text Add to dashboard Cite

Despite an ongoing debate over its efficacy, preimplantation genetic screening (PGS) is increasingly being used to detect numerical chromosomal abnormalities in embryos to improve implantation rates after IVF. The main indications for the use of PGS in IVF treatments include advanced maternal age, repeated implantation failure, and recurrent pregnancy loss. The success of PGS is highly dependent on technical competence, embryo culture quality, and the presence of mosaicism in preimplantation embryos. Today, cleavage stage biopsy is the most commonly used method for screening preimplantation embryos for aneuploidy. However, blastocyst biopsy is rapidly becoming the more preferred method due to a decreased likelihood of mosaicism and an increase in the amount of DNA available for testing. Instead of using 9 to 12 chromosome FISH, a 24 chromosome detection by aCGH or SNP microarray will be used. Thus, it is advised that before attempting to perform PGS and expecting any benefit, extended embryo culture towards day 5/6 should be established and proven and the clinical staff should demonstrate competence with routine competency assessments. A properly designed randomized control trial is needed to test the potential benefits of these new developments.

show abstract

Section: Diagnostic Challengesmentioning

confidence: 99%

Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?

Agarwal

Nagy

2011

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Concerns have been raised regarding whether embryo biopsy and/or freezing with subsequent thaw is harmful for the embryo. Data suggests that TE biopsy does not injure the embryo, and cryopreserved transfer cycles have equivalent to improved outcomes as compared with fresh IVF cycles [10,13,14]. Alternatively, misdiagnosis of the embryo has been identified as a rare but potential risk occurring with all forms of chromosome screening.…”

Section: Commentmentioning

confidence: 99%

“…There are also several ways to obtain genetic material for testing, including polar body biopsy, cleavage-stage embryo biopsy, and blastocyst biopsy. Multiple studies have shown that blastocyst trophectoderm biopsy with CCS is associated with higher implantation and delivery rates as compared to cleavage-stage biopsy [9][10][11]. Furthermore, Yang et al demonstrated that aCGH screening of blastocysts prior to cryopreservation with subsequent thawed embryo transfer resulted in improved implantation rates with low miscarriage rates [12].…”

Section: Introductionmentioning

confidence: 99%

Discrepant diagnosis rate of array comparative genomic hybridization in thawed euploid blastocysts

Tiegs

Hodes-Wertz

McCulloh

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Preimplantation genetic screening (PGS) and diagnosis (PGD) with euploid embryo transfer is associated with improved implantation and live birth rates as compared to routine in vitro fertilization. However, misdiagnosis of the embryo is a potential risk. The purpose of this study was to investigate the clinical discrepant diagnosis rate associated with transfer of trophectoderm-biopsied blastocysts deemed to be euploid via array comparative genomic hybridization (aCGH). Methods This is a retrospective cohort study including cycles utilizing PGS or PGD with trophectoderm biopsy, aCGH, and euploid embryo transfer at a large university-based fertility center with known birth outcomes from November 2010 through July 2014 (n = 520). Results There were 520 embryo transfers of 579 euploid embryos as designated by aCGH. Five discrepant diagnoses were identified. Error rate per embryo transfer cycle was 1.0 %, 0.9 % per embryo transferred, and 1.5 % per pregnancy with a sac. The live birth (LB) error rate was 0.7 % (both sex chromosome errors), and the spontaneous abortion (SAB) error rate was 17.6 % (3/17 products of conception tested, but could range from 3/42 to 7/42). No single gene disorders were mistakenly selected for in any known cases. Conclusions Although aCGH has been shown to be a highly sensitive method of comprehensive chromosome screening, several possible sources of error still exist. While the overall error rate is low, these findings have implications for counseling couples that are contemplating PGS and PGD with aCGH.

show abstract

“…This limitation in FISH technology indicates a need for newer technologies like metaphase comparative genomic hybridization (mCGH), array Comparative Genomic Hybridization (aCGH), Qualitative Polymerase Chain Reaction(qPCR), Single Nucleotide Polymorphism (SNP) array and more recently NextGeneration Sequencing (NGS). These technologies are capable of analyzing all the 23 chromosome pairs from a single cell and have been shown to improve IVF clinical pregnancy rates by 32% in a randomized controlled trial [47][48][49][50][51][52][53][54].…”

Section: Time Lapse Monitoringmentioning

confidence: 99%

Selecting a Single Embryo for Transfer after In-vitro Fertilization: A Translational Medicine Perspective

Faduola¹

2015

Transl Biomed

View full text Add to dashboard Cite

A prospective randomized controlled trial demonstrating significantly increased clinical pregnancy rates following 24 chromosome aneuploidy screening: biopsy and analysis on day 5 with fresh transfer

Cited by 44 publications

References 0 publications

Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?

Preimplantation genetic screening: does it help or hinder IVF treatment and what is the role of the embryo?

Discrepant diagnosis rate of array comparative genomic hybridization in thawed euploid blastocysts

Selecting a Single Embryo for Transfer after In-vitro Fertilization: A Translational Medicine Perspective

Contact Info

Product

Resources

About